West Pharm Beats Q3 EPS by $0.46, Raises FY26 Guidance

West Pharm reported Q3 earnings of $2.66 per share, excluding non-recurring items, $0.46 above expectations. It also beat on revenue and raised FY26 EPS and revenue guidance above consensus.